Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer

Clinical Biochemistry

Volumn 36, Issue 2, 2003, Pages 135-143

  Kyriakopoulou, Lianna G ^a,b   Yousef, George M ^a,b   Scorilas, Andreas ^c   Katsaros, Dionyssios ^d   Massobrio, Marco ^d   Fracchioli, Stefano ^d   Diamandis, Eleftherios P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Cancer genes; Cancer predictive markers; Human stratum corneum chymotryptic enzyme; Kallikreins; KLK7; Ovarian cancer; Prognostic markers; Serine proteases; Tumor markers

Indexed keywords

KALLIKREIN; MESSENGER RNA; PROTEIN SUBUNIT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY TUMOR; PARAMETER; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR VOLUME;

EID: 0037336894     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(02)00446-0     Document Type: Article

References (59)

1. Holschneider C.H., Berek J.S. Ovarian cancer epidemiology, biology, and prognostic factors . Semin Surg Oncol. 19:2000;3-10.
2. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. Cancer J Clin. 50:2000;7-33.
3. Zurawski V.R. Jr, Orjaseter H., Andersen A., Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia relevance for early detection of ovarian cancer . Int J Cancer. 42:1988;677-680.
4. Vasilev S.A., Schlaerth J.B., Campeau J., Morrow C.P. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol. 71:1988;751-756.
5. Rubin S.C., Hoskins W.J., Hakes T.B., Markman M., Reichman B.S., Chapman D., et al. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol. 160:1989;667-671.
6. Bridgewater J.A., Nelstrop A.E., Rustin G.J., Gore M.E., McGuire W.P., Hoskins W.J. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 17:1999;501-508.
7. Meyer T., Rustin G.J. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 82:2000;1535-1538.
8. Chi D.S., Venkatraman E.S., Masson V., Hoskins W.J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol. 77:2000;227-231.
9. Bast R.C. Jr, Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309:1983;883-887.
10. Berek J.S., Bast R.C. Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 76:1995;2092-2096.
11. Stenman U.H., Alfthan H., Vartiainen J., Lehtovirta P. Markers supplementing CA 125 in ovarian cancer. Ann Med. 27:1995;115-120.
12. Yousef G.M., Obiezu C.V., Luo L.Y., Black M.H., Diamandis E.P. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate, and breast tissues, and is hormonally regulated. Cancer Res. 59:1999;4252-4256.
13. Yousef G.M., Diamandis E.P. The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem. 274:1999;37511-37516.
14. Yousef G.M., Diamandis E.P. The expanded human kallikrein gene family locus characterization and molecular cloning of a new member, KLK-L3 (KLK9) . Genomics. 65:2000;184-194.
15. Yousef G.M., Chang A., Diamandis E.P. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem. 275:2000;11891-11898.
16. Yousef G.M., Magklara A., Diamandis E.P. KLK12 is a novel serine protease, and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics. 69:2000;331-341.
17. Yousef G.M., Scorilas A., Jung K., Ashworth L.K., Diamandis E.P. Molecular cloning of the human kallikrein 15 gene (KLK15). Up- regulation in prostate cancer. J Biol Chem. 276:2001;53-61.
18. Yousef G.M., Magklara A., Chang A., Jung K., Katsaros D., Diamandis E.P. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res. 61:2001;3425-3431.
19. Anisowicz A., Sotiropoulou G., Stenman G., Mok S.C., Sager R. A novel protease homolog differentially expressed in breast, and ovarian cancer. Mol Med. 2:1996;624-636.
20. Liu X.L., Wazer D.E., Watanabe K., Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 56:1996;3371-3379.
21. Yoshida S., Taniguchi M., Hirata A., Shiosaka S. Sequence analysis and expression of human neuropsin cDNA and gene. Gene. 213:1998;9-16.
22. Yousef G.M., Diamandis E.P. Expanded human tissue kallikrein family- novel potential cancer biomarkers. Tumour Biol. 23:2002;185-192.
23. Yousef G.M., Diamandis E.P. The new human tissue kallikrein gene family structure, function and association to disease . Endocr Rev. 22:2001;184-204.
24. Diamandis E.P., Yousef G.M. Human tissue kallikrein gene family a rich source of novel disease biomarkers . Expert Rev Mol Diagn. 1:2001;182-190.
25. Diamandis E.P. Prostate-specific antigen-its usefulness in clinical medicine. Trends Endocrinol Metab. 9:1998;310-316.
26. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., Partin A.W. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA) two closely related, but distinct, kallikreins in the prostate . Crit Rev Clin Lab Sci. 35:1998;275-368.
27. Stenman U.H. New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease [editorial; comment]. Clin Chem. 45:1999;753-754.
28. Partin A.W., Catalona W.J., Finlay J.A., Darte C., Tindall D.J., Young C.Y., et al. Use of human glandular kallikrein 2 for the detection of prostate cancer preliminary analysis . Urology. 54:1999;839-845.
29. Magklara A., Scorilas A., Catalona W.J., Diamandis E.P. The combination of human glandular kallikrein and free prostate- specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem. 45:1999;1960-1966.
30. Goyal J., Smith K.M., Cowan J.M., Wazer D.E., Lee S.W., Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res. 58:1998;4782-4786.
31. Kim H., Scorilas A., Katsaros D., Yousef G.M., Massobrio M., Fracchioli S., et al. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer. 84:2001;643-650.
32. Diamandis E.P., Yousef G.M., Soosaipillai A.R., Bunting P. Human kallikrein 6 (zyme/protease M/neurosin) a new serum biomarker of ovarian carcinoma . Clin Biochem. 33:2000;579-583.
33. Luo L., Bunting P., Scorilas A., Diamandis E.P. Human kallikrein 10 a novel tumor marker for ovarian carcinoma? Clin Chim Acta. 306:2001;111-118.
34. Hansson L., Stromqvist M., Backman A., Wallbrandt P., Carlstein A., Egelrud T. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J Biol Chem. 269:1994;19420-19426.
35. Yousef G.M., Scorilas A., Magklara A., Soosaipillai A., Diamandis E.P. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family-genomic characterization, mapping, tissue expression, and hormonal regulation. Gene. 254:2000;119-128.
36. Tanimoto H., Underwood L.J., Shigemasa K., Yan Yan M.S., Clarke J., Parmley T.H., et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer. 86:1999;2074-2082.
37. Obiezu C.V., Scorilas A., Katsaros D., Massobrio M., Yousef G.M., Fracchioli S., et al. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res. 7:2001;2380-2386.
38. Diamandis E.P., Yousef G.M., Soosaipillai A.R., Bunting P. Human kallikrein 6 (zyme/protease M/neurosin) a new serum biomarker of ovarian carcinoma . Clin Biochem. 33:2000;579-583.
39. Hoffman B.R., Katsaros D., Scorilas A., Diamandis P., Fracchioli S., Rigault De La Longras I.A., et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue a new independent unfavorable prognostic marker . Br J Cancer. 87:2002;763-771.
40. Yousef G.M., Kyriakopoulou L.G., Scorilas A., Fracchioli S., Ghiringhello B., Zarghooni M., et al. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer A new independent and favorable prognostic marker . Cancer Res. 61:2001;7811-7818.
41. Luo L.Y., Katsaros D., Scorilas A., Fracchioli S., Piccinno R., Rigault de la Longrais I.A., et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res. 7:2001;2372-2379.
42. Diamandis E.P., Okui A., Mitsui S., Luo L.Y., Soosaipillai A., Grass L., et al. Human kallikrein 11 A new biomarker of prostate and ovarian carcinoma . Cancer Res. 62:2002;295-300.
43. Serov SF, Sorbin LH.Histological typing of ovarian tumors: World Health Organization.1973.
44. Pettersson F. Ann report on the treatment in gynecological cancer. 1994;International Federation of Gynecology and Obstetrics, Stockholm.
45. Day T.G. Jr, Gallager H.S., Rutledge F.N. Epithelial carcinoma of the ovary prognostic importance of histologic grade . Natl Cancer Inst Monogr. 42:1975;15-21.
46. Wittwer C.T., Herrmann M.G., Moss A.A., Rasmussen R.P. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques. 22:1997;130-131. 134-8.
47. Bieche I., Onody P., Laurendeau I., Olivi M., Vidaud D., Lidereau R., et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem. 45:1999;1148-1156.
48. Bieche I., Olivi M., Champeme M.H., Vidaud D., Lidereau R., Vidaud M. Novel approach to quantitative polymerase chain reaction using real-time detection application to the detection of gene amplification in breast cancer . Int J Cancer. 78:1998;661-666.
49. Birren B., Green E.D., Klapholz S., et al. Genome Analysis A Laboratory Manual . 1998;Cold Spring Harbor Laboratory Press, Plainview, NY.
50. Woo T.H., Patel B.K., Cinco M., Smythe L.D., Symonds M.L., Norris M.A., et al. Real-time homogeneous assay of rapid cycle polymerase chain reaction product for identification of Leptonema illini. Anal Biochem. 259:1998;112-117.
51. Cox D.R. Regression models and life tables. R Stat Soc B. 34:1972;187-202.
52. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
53. Ekholm E., Egelrud T. Stratum corneum chymotryptic enzyme in psoriasis. Arch Dermatol Res. 291:1999;195-200.
54. Egelrud T. Purification and preliminary characterization of stratum corneum chymotryptic enzyme a proteinase that may be involved in desquamation . J Invest Dermatol. 101:1993;200-204.
55. Godwin A.K., Testa J.R., Hamilton T.C. The biology of ovarian cancer development. Cancer. 71:1993;530-536.
56. Langdon S.P., Hawkes M.M., Lawrie S.S., Hawkins R.A., Tesdale A.L., Crew A.J., et al. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer. 62:1990;213-216.
57. Murdoch W.J. Perturbation of sheep ovarian surface epithelial cells by ovulation evidence for roles of progesterone and poly(ADP-ribose) polymerase in the restoration of DNA integrity . J Endocrinol. 156:1998;503-508.
58. Munstedt K., Steen J., Knauf A.G., Buch T., von Georgi R., Franke F.E. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer. 89:2000;1783-1791.
59. Magklara A., Scorilas A., Katsaros D., Massobrio M., Yousef G.M., Fracchioli S., et al. The human KLK8 (neuropsin/ovasin) gene Identification of two novel splice variants and its prognostic value in ovarian cancer . Clin Cancer Res. 7:2001;806-811.